Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

This publication has 26 references indexed in Scilit:

• Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells
  Clinical Cancer Research, 2006
• Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma
  Cancer Research, 2006
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
  The Journal of Experimental Medicine, 2005
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment
  Clinical Cancer Research, 2005
• Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
  Journal of Clinical Oncology, 2005
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients
  Clinical Cancer Research, 2005
• Selective CD4⁺ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications
  Journal of Clinical Oncology, 2004
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
  Science, 2002
• Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
  The Journal of Experimental Medicine, 1982